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Parkinson’s disease (PD) is associated with increased mortality despite many advances in treatment. Following the introduction
of levodopa in the late 1960’s, many studies reported improved or normalized mortality rates in PD. Despite the remarkable
symptomatic benefits provided by levodopa, multiple recent studies have demonstrated that PD patients continue to die at a rate
in excess of their peers. We undertook this retrospective study of 211 deceased PD patients to determine the factors associated with
mortality in levodopa-treated PD. Our findings confirm that PD is associated with increased mortality in both men and women.
Unlike the majority of other mortality studies, we found that women have a greater reduction in lifespan compared to men. We
also found that patients with early onset PD (onset at the age of 50 or before) have reduced survival relative to PD patients with
later ages of onset. A final important finding is that survival is equal in PD patients treated with levodopa early (within 2 years or
less of PD onset) versus later.
1. Introduction
Before the introduction of levodopa, mortality in idiopathic
PD was 2.9 times higher than that of the general population
adjusted for age, gender, and race [1]. When levodopa was
introduced in the late 1960’s, PD patients realized remarkable
symptomatic benefits and in multiple subsequent cross-
sectional studies levodopa appeared to ameliorate or normal-
ize mortality rates in PD [2–7]. Some authors found that lev-
odopa reduced PD mortality during the first 6 years of ther-
apy, with mortality returning to near prelevodopa levels after
12 years of treatment [8]. As one author reports, however, the
majority of studies over the past 30 years have demonstrated
that levodopa treatment in PD does not normalize mortality
rates and these patients continue to die at a rate in excess
of their peers [9]. More recent reports (1999–2004) have
demonstrated a standardized mortality ratio (SMR) in PD
patients ranging from 1.52 in a community-based Norwegian
study [10] to a relative mortality risk of 3.38 in door-to-door
survey in Ilan County, Taiwan [11].
Some factors such as severity of Parkinson’s symptoms
[12] and the presence of dementia [12–14] appear to increase
mortality risk in PD. Many other factors such as gender, age
of onset, disease duration, or delay in initiation of levodopa
therapy may also affect mortality. Defining factors associated
with increased mortality in PD is important as these factors
may help clinicians anticipate outcomes and may influence
therapeutic decisions.
2. Patients and Methods
The University of Virginia Movement Disorders Database
was screened for deceased patients who were diagnosed with
idiopathic PD and chronically treatedwith levodopa. Patients
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Table 1: Disease characteristics of deceased PD patients.
𝑛
Total sample (𝑛 = 211) Men (𝑛 = 134) (64%) Women (𝑛 = 77) (36%) P
Range Mean (SD) Mean (SD) Mean (SD)
Age of onset 211 33–87 64 (11) 64 (11) 63 (10) 0.60
Age at death 211 41–95 75 (8) 75 (8) 76 (7) 0.84
Disease duration 211 1–37 12 (7) 12 (7) 12 (7) 0.41
who were diagnosed with vascular or drug-induced parkin-
sonism, as well as Parkinson’s plus syndromes, were excluded
from this analysis. Two hundred and eleven deceased patients
who were diagnosed clinically with PD were retrospectively
identified from the database. Patients had died between the
years 1984 and 2002 with the mean year of death being 1996.
Patients were diagnosed with PD using UK Parkinson’s Dis-
ease Society Brain Bank criteria [15]. Our historical clinical
diagnostic accuracy is 91% based upon autopsy of our patient
population (G. F. Wooten, unpublished data) and is similar
to that reported by other groups [16]. Only patients treated
with levodopa throughout the course of their illness were
included in this study (𝑛 = 211). Each patient was evaluated
at least once at our institution by a movement disorders-
trained neurologist (JPB, MBH, JMT, or GFW).Themajority
of patients were followed throughout their illness until
death. We determined the cause of death (COD) in 197
patients by the review of medical records, discussion with
the treating physician(s), interview of the decedent’s relatives,
and review of autopsy findings (available in 16 patients—6
patients underwent neuropathological investigation only and
10 patients had complete autopsy). All autopsied patients met
neuropathological criteria for PD. Cause of death was con-
sidered to be PD if the patient died of complications related
to PD (e.g., falls or aspiration pneumonia).
For each patient in this sample, age at PD onset and year
of PD onset were used to create an age-, race-, and gender-
matched control from the U.S. population based upon annual
U.S. Life Expectancy Tables (U.S. Center for National Health
Statistics, Vital Statistics of the United States). For patients
with PDonset or death after age 85,decennialU.S.LifeExpect-
ancy Tables were used. For example, if a Caucasian man had
PD onset at age 62 in 1990, then the 1990 U.S. Life Expectancy
tables were used to determine the expected lifespan of a
Caucasian man who was at the age of 62 in 1990 to create a
control for this patient. The expected lifespan of controls was
compared to the actual lifespan of the patient sample for
analysis. The probability of each patient dying given their age
of onset and disease duration was also determined using the
appropriate United States Life Tables as described by Dia-
mond andMarkham [4].The number of expected deaths was
determined by summing the individual probabilities of death
for each patient as described by Diamond and Markham [4].
Mortality ratios were calculated as the ratio of observed to
expected deaths.
The medical records of the deceased PD patients were
also screened for levodopa treatment parameters: time from
PD onset until initiation of levodopa therapy (L-dopa delay),
duration of levodopa therapy (L-dopa duration), and maxi-
mum levodopa dose (L-dopa max). These parameters were
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Figure 1: Survival analysis of all PD patients versus age-, gender-,
and race-matched controls from the U.S. population. Controls had
a seven-year longer survival on average relative to PD patients.
available for 197 patients for L-dopa delay and L-dopa dura-
tion and 169 patients for L-dopa max.
Data were analyzed using chi-square analysis for categor-
ical variables and Student’s 𝑡-test or theMann-Whitney𝑈 test
for continuous variables. Kaplan-Meier analysis was used to
estimate survival when comparing groups of patients. Logis-
tic regression was performed to identify clinical characteris-
tics that were associated with patients dying of PD or other
causes. All deceased PD patients were stratified by cause of
death into two groups (PD and not PD) and then, through
logistic regression, the variables of age of onset, age at death,
gender, disease duration, L-dopa delay, and L-dopa duration
were examined. Statistical analysis was performed using SPSS
for Windows (SPSS, Inc., Chicago, IL).
3. Results
Table 1 displays the disease characteristics of the 211 deceased,
levodopa-treated PD patients in the study. Two hundred and
seven patients were Caucasian and four were African-Amer-
ican (data not shown in Table 1). Approximately two-thirds of
the patients were men and there were no differences between
men and women in the sample with regards to age of onset,
age at death, or disease duration.
A Kaplan-Meier survival analysis illustrated in Figure 1
reveals that survival is reduced on average by 7 years in
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Figure 2: Survival analysis of PDmen andPDwomen versus control
men and control women from the U.S. population. PD men and PD
women have no difference in survival, while both PD men and PD
women have reduced survival relative to control men and control
women, respectively.
the entire sample of PDpatients compared to an age-, gender-,
and race-matched control group from the U.S. population.
Menwith PD had amean reduction in lifespan of 5 years rela-
tive to male controls while women with PD had their lifespan
reduced by 7 years compared to female controls (Figure 2).
Women with PD (𝑛 = 77) had a greater reduction in lifespan
relative to men with PD (𝑛 = 134) (𝑃 < 0.001). There was
no difference in survival between men and women with PD
in our sample (Figure 2). When the probabilities of each
patient dying were calculated as described by Diamond and
Markham [4] using annual or decennial U.S. Life Tables, the
overall observed to expected mortality ratio for the 211 PD
patients was 2.66. Mortality ratios were 2.28 for PD men
and 3.76 for PD women relative to age-, gender-, and race-
matched controls from the U.S. population.
Early age of onset (defined as PDonset at age 50 or earlier)
was associated with longer disease duration in our sample
(Figure 3). Patients with early age of onset (𝑛 = 29) were 12
years younger at death (65 ± 8 versus 77 ± 6, 𝑃 < 0.001) and
had a longer disease duration (20±8 versus 11±6, 𝑃 < 0.001)
when compared to patients with onset after age 50 (𝑛 = 182).
Kaplan-Meier survival analysis revealed markedly reduced
survival in early onset patients compared to patients with ages
of onset after the age of 50 (Figure 4). Mortality ratios were
3.58 and 2.57, respectively, for the 29 patients with early PD
onset versus the 182 patients with PD onset after the age of
50.
Cause of death by clinical impression (clinical history and
medical records) was determined for 197 of the 211 patients
and the frequencies for each cause of death are displayed
in Table 2. About half of the patients died of PD-related
causes with cardiovascular disease, cancer, and stroke causing
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Figure 3: Scatter plot comparing age of onset to disease duration
for each PD patient in our sample. Earlier age of PD onset was
associated with longer disease duration in our sample as indicated
by the trendline.
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Figure 4: Survival analysis of PD patients with early age of onset
(at age 50 or earlier) and later ages of onset. PD patients with early
age of onset had markedly reduced survival (12 years) relative to the
patients with later ages of onset.
the deaths in the remainder of the sample. There was no
gender difference in the number of patients dying of PD-
related causes versus non-PD causes (data not shown) (𝑃 =
0.315). When patients were categorized into intervals of 5
years disease duration, equal proportions of patients died of
PD versus other causes irrespective of PD disease duration
(data not shown) (𝑃 = 0.241).
Full autopsies were performed in ten patients and neu-
ropathological diagnoses were available for six additional
patients (Table 3). All patients met neuropathological criteria
for PD at autopsy (16 of 16 patients) with two patients also
meeting criteria for the diagnosis of diffuse Lewy body dis-
ease (DLBD) [17]. Two of these 16 patients also met CERAD
criteria [18] for Alzheimer’s disease in addition to their PD
neuropathological diagnosis. The majority of fully autopsied
patients died of bronchopneumonia (five of ten patients) with
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Table 2: Cause of death by clinical impression.
Cause of death 𝑛 %
Parkinson’s disease 111 52.6
Cardiovascular disease 26 12.3
Cancer 18 8.5
Stroke 14 6.6
Renal disease 9 4.3
Suicide 5 2.4
Respiratory disease/illness 4 1.9
Other neurological 4 1.9
Other medical 3 1.4
Diabetes 2 0.9
Old age 1 0.5
Unknown 14 6.6
Table 3: Neuropathology and cause of death by autopsy.
Neuropathology (𝑛 = 16) 𝑛
Parkinson’s disease 12
Diffuse Lewy body disease 2
Parkinson’s disease and Alzheimer’s disease 2
Cause of death (𝑛 = 10) 𝑛
Bronchopneumonia 5
Breast cancer 1
Lymphoma 1
Myocardial infarction 1
Hip fracture 1
Unknown 1
one patient dying of complications related to a hip fracture.
This indicates that six of ten patients that underwent full
autopsy died of PD-related causes.
Table 4 illustrates mortality in patients when stratified by
age at death and disease duration. Four of eight patients dying
at the age of 60 or earlier died of PD.The vast majority (83%)
of patients died between the ages of 66 and 85. Eighty-nine
percent of patients diedwithin 20 years of their PD onset with
only 11% of patients survivingwith PD formore than 20 years.
Equal proportions of patients died of PD regardless of age at
death (𝑃 = 0.614) or disease duration (𝑃 = 0.244).
Table 5 displays levodopa treatment parameters for
patients in the study. The delay from the time of PD onset
until starting levodopa (L-dopa delay) and levodopa treat-
ment duration (L-dopa duration) were available in 197
patients in the study.The levodopamaximum dose was avail-
able in 169 study patients. Levodopa maximum dose (L-dopa
max) for patients in the study was equal in men and women.
Kaplan-Meier survival analysis revealed equal survival in
patients who started levodopa within the first two years of PD
onset (𝑛 = 89) compared to those starting levodopa later (𝑛 =
108) (75(76) versus 76(76), 𝑃 = 0.27).
4. Discussion
This is one of the larger studies (211 patients) of mortality in
PD since the levodopa era in PDbegan [1].Themajor findings
are as follows: (1) levodopa-treated PDpatients appear to have
excess mortality relative to controls from the U.S. population,
(2) there does not appear to be a difference between men
and women with PD with regard to death rate, but perhaps
because control women live longer than control men, women
with PD have increased mortality and a greater reduction in
lifespan compared tomenwith PD, (3) patients with early PD
onset (age 50 or earlier) appear to have increased mortality
relative to patients with later PD onset, and (4) survival
appears equal in PD patients treated with levodopa early
(within 2 years of PD onset) versus later.
Methods for determining the effect of PD on mortality
vary from retrospective to prospective, cross-sectional to lon-
gitudinal and may involve small cohorts or even entire popu-
lations. Despite differences in methodology, the vast majority
of studies demonstrate that patients with PD continue to die
at a rate in excess of controls [9]. Our results agree with these
findings and demonstrate increased mortality in levodopa-
treated PD patients relative to age-, race-, and gender-
matched controls from theU.S. population.Themost straight-
forward interpretation of these results is that levodopa, while
effectively treating themotor symptoms of PD and improving
life expectancy, does not normalize life expectancy in PD
patients. Even though levodopa may improve motor symp-
toms in PD (tremor, bradykinesia, and rigidity), it may not
slow disease progression [19]. As PD progresses, levodopa-
resistant motor symptoms (speech/swallowing impairment,
gait, and balance problems) and nonmotor symptoms (auto-
nomic dysfunction, mood disorders, cognitive impairment,
sleep disorders, and psychosis) become more prevalent and
may contribute to increased morbidity and mortality [20].
Given the average disease duration of 12 years in our patient
sample, it is likely that many of our patients suffered both
levodopa-resistantmotor and nonmotor symptoms thatmost
likely contributed to increased morbidity and mortality.
The strengths of our study are (1) a well-defined and
characterized sample of idiopathic PD patients with minimal
contamination by other forms of parkinsonism, unlike some
studies [21–23] and (2) a very large number of PD patients
ascertained who were followed until death. A major limita-
tion of this study is that the retrospective design may intro-
duce a selection bias toward older patients or those withmore
prolonged or severe PD who were more likely to die. This
weakness is partially mitigated by the very long ascertain-
ment period of almost 20 years. In addition, the clinical char-
acteristics of PD patients in our sample are similar tomultiple
retrospective/prospective studies with respect to age of PD
onset, disease duration [2, 3, 7], and age at death [2, 24–26].
Another potential source of bias in our study is the setting
of a specialty clinic in an academic medical center that might
select for a population of patients withmore severe or difficult
tomanage PD compared to community-based populations. It
is important to note, however, that our retrospective deceased
PD patient sample had a similar age of onset, disease dura-
tion, and age at death as studies described above in multiple
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Table 4: Mortality in PD patients stratified by age at death and disease duration.
Age at death Percentage of totaldead Observed deaths Expected deaths Mortality ratio Number of PD deaths
41–45 0.5 1 0.0189 52.91 0
46–50 0.5 1 0.0263 38.02 0
51–55 0.9 2 0.0778 25.71 1
56–60 1.9 4 0.6277 6.37 3
61–65 5.7 12 1.5998 7.50 5
66–70 13.3 28 6.3265 4.43 11
71–75 19.9 42 11.9488 3.52 24
76–80 33.2 70 26.5476 2.64 39
81–85 16.1 34 18.5483 1.83 20
86–90 7.6 16 12.5786 1.27 7
91–95 0.5 1 1.0000 1.00 1
Disease duration Percentage of totaldead Observed deaths Expected deaths Mortality ratio Number of PD deaths
1–5 17.5 37 7.0770 5.23 16
6–10 29.4 62 20.7956 2.98 28
11–15 25.6 54 23.7313 2.28 34
16–20 16.6 35 15.9910 2.19 22
21–25 8.1 17 7.7683 2.19 8
26+ 2.8 6 3.9371 1.52 3
Table 5: Levodopa treatment parameters.
𝑛
Total sample (𝑛 = 211) Men Women
𝑃
Range Mean (SD) 𝑛 Mean (SD) 𝑛 Mean (SD)
L-dopa delay 197 0–15 2 (3) 124 2 (3) 73 3 (3) 0.31
L-dopa duration 197 1–30 9 (6) 124 9 (6) 73 9 (6) 0.66
L-dopa max 169 150–2250 833 (429) 108 870 (441) 61 767 (403) 0.16
L-dopa delay: years from PD onset until L-dopa initiation; L-dopa duration: years of L-dopa treatment; L-dopa max: maximum recorded L-dopa dose in
milligrams.
clinical settings ranging from a single academic medical
center [27] to a multicenter study [26], to a population-based
study [28].
We observed a higher overall mortality ratio (2.66) in our
retrospective deceased PD patient sample relative to some
recently published prospective studies [29, 30]. The higher
mortality ratio observed in our study may reflect the retro-
spective design bias given that at least two recent prospective
studies have found much lower standardized mortality ratios
of 1.1 in a Chinese cohort and 1.29 in a UK cohort [29, 30].
On the other hand, someprospective cohort- andpopulation-
based studies have recently found standardized mortality
ratios ranging from 1.86 at 15 years to 3.1 at 20 years in the
SydneyMulticentre Study of PD to as high as 3.6 in a popula-
tion-based study of PD mortality in Bulgaria [31–33].
Our sample of deceased levodopa-treated PD patients
shows a preponderance ofmen (64% of patients in the study).
Similar to our results,most PDmortality studies have demon-
strated an increased incidence in men [34–43]. This parallels
our finding that men have 1.5 times the relative risk of devel-
oping PD based upon a meta-analysis of seven population-
based incidence studies [44]. The reasons for the higher
incidence of PD in men are unknown and might repre-
sent differences in genetic susceptibility [45], environmental
exposure [46], head trauma, or increased female resistance to
developing PD (perhaps due to the neuroprotective effects of
estrogen) [47, 48].
Our data also demonstrate that women have higher mor-
tality ratios compared to men (3.76 and 2.28, resp.) while
having a similar age at death. This confirms the findings of
Wooten et al. [44] and reflects a greater reduction in survival
for women, given that women without PD typically live
longer than men. This implies that women who get PD may
lose (or have lost) putative longevity factors present in other
women.This also indicates that PDprogression is no different
between women and men with respect to mortality.
Contrary to our findings, many authors found that men
had greater mortality risk [34–43]. Other authors, however,
6 Parkinson’s Disease
found greater mortality risk in women in both pre-levodopa
era [1] and more recently [7, 8, 49, 50]. Methodological dif-
ferences in some of these studies may account for differences
in mortality since sex-specific mortality tables were not used
by some authors [39].
Complications of PD resulted in the death of over half
of our patients (Table 2) similar to other studies [26, 34].
Autopsy results reveal almost 100% clinical diagnostic accu-
racy for PD in our group similar to other groups [16]. When
patients were stratified by age at death and disease duration
(Table 3), it is clear that PD contributed to the excess mor-
tality of patients dying after the age of 50. This analysis
also demonstrates that PD may contribute to many deaths
regardless of disease duration. Patients with shorter disease
durations dying of PD were older with presumably more
comorbidities or may have had more aggressive disease [51].
Patients with early PDonset (age 50 or less) in our sample,
while having a slower disease progression [51], actually died
at amuch younger age and had increasedmortality relative to
patients with ages of onset greater than 50. One prospective,
cross-sectional study found similar mortality ratios in three
groups of PD patients with mean ages of onset of 43, 55, and
66 years [51]. All patients in the three groups were followed
for 17 years; however, patients with early age of onset in our
study had a mean disease duration of 20 years, meaning that
many of the early onset patients in the Diamond et al. [51]
study probably had not died yet. Our finding of a highermor-
tality ratio in early onset PD patients is consistent with our
ability to capture a greater number of early onset PD patients
at death than if we followed them for 17 years. Because PD
contributes to the death of similar ratios of early onset and
later onset patients in our study, it is likely that PD signifi-
cantly contributes to the increased mortality in an otherwise
“healthier” age group when compared to older onset PD
patients.
Supporting this, hypotheses are data from a more recent
study of young-onset PD (YOPD) patients (defined as onset
from age 21 to 40) [52]. The median age of deceased YOPD
patients in the cohort was 57.7 years with a disease duration of
22.5 years while the median age of living YOPD patients was
50.1 years with a disease duration of 16.9 years [52].
Some in vitro studies have suggested that levodopa is toxic
to dopaminergic neurons [53]. This has led to the hypothesis
that levodopa might hasten progression of dopaminergic
neuron death as well as morbidity and mortality in patients
with PD. Our data indicate that survival was no better or
worse in patients starting levodopa within two years of symp-
tom onset versus greater than two years after symptom onset.
The effect of levodopa on PD progression and mortality
remains controversial despite its obvious symptomatic ben-
efits for PD patients [54, 55].
The average disease duration for patients with PD in
Hoehn and Yahr’s seminal study published in 1967 was 9.4
years [1]. Thirty-five years after Cotzias et al. demonstrated
that levodopa had long-term beneficial effects in PD [56], the
average life expectancy for levodopa-treated PD patients after
symptom onset is 12 years (in this study). The increase in
survival could be due to the effects of levodopa therapy or
other pharmacotherapies in PD, improved treatments for
comorbid medical conditions such as cancer, diabetes, and
heart disease, better and more available healthcare for
patients, improved surgical treatments, and possibly healthier
lifestyles.
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